A. Lens-Pardo

Establishment of patient-derived xenografts for neuroendocrine tumors in the avian embryo model

Nilakshi Kulathunga, Rusha Chakraborty, Yan Li, Emmanuel Chérin et autres

Elucidating the mechanisms underlying cancer progression and identifying tailored therapies for patients can be enhanced by using patient-derived preclinical models. In this study, we investigated whether patient-derived xenograft (PDX) models of well-differentiated neuroendocrine tumors (NETs) could be established in the avian embryo …

1143O Refining molecular classification of neuroendocrine tumors from diverse origins using multi-omic integration models: Unveiling novel neuroendocrine subtypes and their clinical implications

C. Carretero-Puche, B. Antón Pascual, A. Lens-Pardo, Marta Benavent Viñuales et autres

es (code pays fourni par la source)

1144O Osteopontin (OPN) predicts the efficacy of anti-angiogenic therapy with multikinase inhibitors (MKIs) in advanced neuroendocrine tumors (NETs): Underlying molecular mechanisms

A. Lens-Pardo, C. Carretero-Puche, B. Antón Pascual, J. Capdevila Castillón et autres

es (code pays fourni par la source)

28MO Predictive biomarkers of response to axitinib in patients with advanced EP-NETs enrolled in the AXINET trial (GETNE 1107): Underlying molecular mechanisms

A. Lens-Pardo, C. Carretero-Puche, B. Antón Pascual, J. Capdevila Castillón et autres

34P Genomic profiling of NEN patients: Prognostic and therapeutic relevance

B. Antón Pascual, A. Modrego, A. La Salvia, A. Lens-Pardo et autres